Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.
What is Mary Reumuth's net worth?
The estimated net worth of Mary Reumuth is at least $452,017.37 as of January 6th, 2025. Ms. Reumuth owns 68,581 shares of KALA BIO stock worth more than $452,017 as of March 26th. This net worth estimate does not reflect any other investments that Ms. Reumuth may own. Learn More about Mary Reumuth's net worth.
How old is Mary Reumuth?
Ms. Reumuth is currently 49 years old. There are 5 older executives and no younger executives at KALA BIO. The oldest executive at KALA BIO is Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer, who is 71 years old. Learn More on Mary Reumuth's age.
How do I contact Mary Reumuth?
The corporate mailing address for Ms. Reumuth and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at hannah.deresiewicz@sternir.com. Learn More on Mary Reumuth's contact information.
Has Mary Reumuth been buying or selling shares of KALA BIO?
Within the last three months, Mary Reumuth has sold $13,016.78 in shares of KALA BIO stock. Most recently, Mary Reumuth sold 1,706 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a transaction totalling $13,016.78. Following the completion of the sale, the chief financial officer now directly owns 68,581 shares of the company's stock, valued at $523,273.03. Learn More on Mary Reumuth's trading history.
Who are KALA BIO's active insiders?
Are insiders buying or selling shares of KALA BIO?
In the last twelve months, KALA BIO insiders bought shares 1 times. They purchased a total of 310,559 shares worth more than $1,999,999.96. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 44,761 shares worth more than $255,095.17. The most recent insider tranaction occured on January, 6th when insider Darius Kharabi sold 2,021 shares worth more than $15,420.23. Insiders at KALA BIO own 8.3% of the company.
Learn More about insider trades at KALA BIO. Information on this page was last updated on 1/6/2025.
